Barclays PLC Has $57,000 Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Barclays PLC boosted its position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 86.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 27,165 shares of the company’s stock after buying an additional 12,564 shares during the period. Barclays PLC’s holdings in Prelude Therapeutics were worth $57,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Massachusetts Financial Services Co. MA raised its position in Prelude Therapeutics by 2.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after purchasing an additional 14,226 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Prelude Therapeutics by 103.2% in the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock valued at $111,000 after buying an additional 14,769 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Prelude Therapeutics by 32.2% in the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after buying an additional 15,682 shares during the last quarter. XTX Topco Ltd acquired a new position in Prelude Therapeutics during the 3rd quarter worth about $100,000. Finally, Walleye Capital LLC grew its holdings in Prelude Therapeutics by 446.2% during the 3rd quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after acquiring an additional 67,946 shares during the last quarter. Institutional investors own 79.72% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on PRLD shares. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research note on Wednesday, December 11th.

Insider Buying and Selling

In other Prelude Therapeutics news, insider Andrew Combs purchased 60,000 shares of the stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $1.37 per share, for a total transaction of $82,200.00. Following the completion of the acquisition, the insider now directly owns 377,623 shares of the company’s stock, valued at $517,343.51. The trade was a 18.89 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Krishna Vaddi acquired 100,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were acquired at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the acquisition, the chief executive officer now directly owns 1,167,275 shares in the company, valued at $1,085,565.75. This represents a 9.37 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 198,075 shares of company stock valued at $213,486 in the last 90 days. 62.80% of the stock is owned by insiders.

Prelude Therapeutics Stock Performance

Shares of PRLD stock opened at $1.14 on Friday. The firm’s 50 day moving average price is $1.10 and its two-hundred day moving average price is $2.92. Prelude Therapeutics Incorporated has a 52-week low of $0.80 and a 52-week high of $6.80. The stock has a market cap of $62.74 million, a PE ratio of -0.64 and a beta of 1.39.

Prelude Therapeutics (NASDAQ:PRLD) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. The company had revenue of $3.00 million for the quarter. As a group, sell-side analysts predict that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.